Skip to main content

Pharmaceutical Price Regulation Scheme PPRS Payment for 2017

Statement made on 20 January 2017

Statement UIN HCWS426

Statement

On 23rd December 2016, the Government published the level of payment due from members of the Pharmaceutical Price Regulation Scheme (PPRS) in 2017 to keep health service spend on branded medicines within the levels agreed under the Scheme.

The Department of Health and the Association of the British Pharmaceutical Industry have agreed in principle to amend Chapter 6 of the 2014 PPRS in accordance with paragraph 3.4 of the scheme in order that the scheme continues to deliver its agreed objectives of predictability and stability to Government and industry, and ensuring that the cost of branded medicines to the NHS stays within affordable limits. The effect of the changes is that the payment percentage for 2017 is to be set at 4.75% for 2017, and the 2018 PPRS payment percentage will be determined by reference to the existing PPRS payment mechanism, provided that the resulting percentage falls within the lower and upper limits of 2.38% and 7.80%. The Government recognises the additional contribution being made by the pharmaceutical industry in acknowledgement of the financial challenges facing the NHS.

The Department has published a document setting out further details entitled “Pharmaceutical Price Regulation Scheme (PPRS) 2014: revised payment percentages at December 2016”. A copy is attached.

Linked statements

This statement has also been made in the House of Lords

Department of Health
Pharmaceutical Price Regulation Scheme PPRS Payment for 2017
Lord O'Shaughnessy
Parliamentary Under-Secretary of State for Health
Conservative, Life peer
Statement made 23 January 2017
HLWS428
Lords